Publication:
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?

Simple item page
dc.contributor.authorKocaturk, E.
dc.contributor.authorBaskan, E. B.
dc.contributor.authorEngin, B.
dc.contributor.authorOzdemir, M.
dc.contributor.authorKÜÇÜK, ÖZLEM SU
dc.contributor.authorCan, P.
dc.contributor.authorOrnek, S.
dc.contributor.authorHasal, E.
dc.contributor.authorAtakan, N.
dc.contributor.institutionauthorSU KÜÇÜK, ÖZLEM
dc.date.accessioned2020-10-22T19:23:47Z
dc.date.available2020-10-22T19:23:47Z
dc.date.issued2019-08-01T00:00:00Z
dc.identifier.urihttp://hdl.handle.net/20.500.12645/24428
dc.identifier.wosWOS:000480254003224
dc.subjectKocaturk E., Baskan E. B. , Engin B., Ozdemir M., KÜÇÜK Ö. S. , Can P., Ornek S., Hasal E., Atakan N., -Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?-, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Lisbon, Portekiz, 1 - 05 Haziran 2019, cilt.74, ss.484-485
dc.titleOmalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?
dc.typeConference Paper
dspace.entity.typePublication
local.avesis.idb404d1c8-a0ed-4cc3-9600-4d86b31bf815
local.publication.isinternational1
relation.isAuthorOfPublicationfd8dc121-9bbe-4ee4-a2fd-5e237676169d
relation.isAuthorOfPublication.latestForDiscoveryfd8dc121-9bbe-4ee4-a2fd-5e237676169d
Files
Collections
Yayınlar - Eserler